
Privi Q2 FY27: Consolidated PAT +30% YoY to ₹117.5 Cr as margins expand, beats Street
Privi Speciality Chemicals' consolidated results for the quarter ended September 30, 2026 (Q2 FY27) comfortably cleared the bar set by our pre-result preview. Revenue from operations came in at ₹760.45 Cr, above the previewed ₹680-710 Cr range and up 12.0% YoY (₹678.71 Cr) and 14.1% QoQ (₹666.22 Cr). Consolidated PAT of ₹117.53 Cr was up 30.3% YoY and 41.9% QoQ, well clear of the ₹82-92 Cr the preview flagged as on-plan — a clean beat on both lines, consistent with Motilal Oswal's pre-result Buy thesis built on the medium-term execution case. No exceptional or one-off items are disclosed in either the standalone or consolidated statements this quarter, so the growth is on a like-for-like basis. Margins did the heavy lifting behind the profit beat. Consolidated EBITDA margin (PBT adjusted for other income, finance cost and depreciation, over revenue from operations) worked out to ~26.3%, recovering sharply from Q1 FY27's ~22.9% and roughly matching the year-ago quarter's 26.8% — back near the >25% level management has guided it will sustain. Net profit margin (PAT over total income) expanded to ~15.2%, up from 13.3% a year ago and 12.2% last quarter. Standalone PAT of ₹119.3 Cr was broadly in line with the consolidated figure (~1.5% higher), so there's no material standalone-versus-consolidated divergence to flag. On guidance, management's medium-term target of ₹5,000 Cr revenue and ₹1,000+ Cr EBITDA within 3-4 years (20% CAGR) is only partly on track: this quarter's 12.0% YoY revenue growth trails the 20% CAGR pace, even as the ~26.3% EBITDA margin print is already running ahead of the "around 25%" margin guidance from the last call — margin delivery is ahead of plan while topline growth needs to accelerate to hit the multi-year target. The company did not issue an accompanying press release or MD&A commentary with this filing, so there is no fresh management quote to weigh against the numbers; the only qualitative colour this quarter comes from the board's other actions disclosed alongside the results — a first interim dividend of ₹5/share (record date November 4, 2026) and the October 27, 2026 shareholder approval of the NCLT-directed Scheme of Amalgamation. Going into Q3 FY27, the two threads to track are whether revenue growth reaccelerates toward the 20% CAGR guided pace — tied to the delayed Phase-1 capacity move from 48K to 54K MT originally targeted for September 2026 — and whether the current ~26% EBITDA margin holds as that capacity ramps, alongside the Phase-2 expansion to 66K MT by September 2027 backed by ₹850-900 Cr of planned capex.
Key Highlights
- Consolidated revenue ₹760.45 Cr, up 12.0% YoY and 14.1% QoQ — above the pre-result preview range of ₹680-710 Cr
- Consolidated PAT ₹117.53 Cr, up 30.3% YoY and 41.9% QoQ — well above the previewed ₹82-92 Cr range
- NPM expanded to ~15.2% (vs 13.3% YoY, 12.2% QoQ); EBITDA margin ~26.3% (vs 26.8% YoY, 22.9% QoQ) — margin recovery back near management's >25% sustain guidance
- Standalone PAT ₹119.3 Cr vs consolidated ₹117.5 Cr — no material divergence between the two
- Board declared first interim dividend of ₹5/share (FV ₹10) for FY27; record date Nov 4, 2026, payment by Nov 25, 2026
- Scheme of Amalgamation cleared its shareholder vote on Oct 27, 2026 pursuant to the NCLT order
- EPS (consolidated, not annualised) ₹29.96 for the quarter vs ₹21.56 in Q1 FY27 and ₹24.04 a year ago
Price Impact
More from PRIVISCL